A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is
safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic)
human epidermal growth factor receptor 2 (HER2)-expressing cancer.